ERBB2 and neoplasm: Additionally, survival benefits in DFS for patients with poor tumor differentiation (HR, 0.73 95% CI [0.54–0.98]; P = 0.036), 0–50% positive lymph node ratio (HR, 0.69, 95% CI [0.49–0.97]; P = 0.032), II-IIIB tumor stage (HR, 0.69, 95% CI [0.50–0.94]; P = 0.020) and negative HER-2 expression (HR, 0.72, 95% CI [0.54–0.97]; P = 0.031) in CRT group (Fig. 4A).